Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001245038 | SCV001418299 | uncertain significance | Glycogen storage disease, type II | 2022-07-02 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 815 of the GAA protein (p.Asn815Ser). This variant is present in population databases (no rsID available, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with GAA-related conditions. ClinVar contains an entry for this variant (Variation ID: 969645). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001786455 | SCV002028845 | uncertain significance | not provided | 2021-05-26 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004034812 | SCV003531556 | uncertain significance | Cardiovascular phenotype | 2022-06-10 | criteria provided, single submitter | clinical testing | The c.2444A>G (p.N815S) alteration is located in exon 17 (coding exon 16) of the GAA gene. This alteration results from a A to G substitution at nucleotide position 2444, causing the asparagine (N) at amino acid position 815 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001786455 | SCV003828480 | uncertain significance | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001245038 | SCV002094458 | uncertain significance | Glycogen storage disease, type II | 2020-03-14 | no assertion criteria provided | clinical testing |